Your browser doesn't support javascript.
loading
Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Iwamoto, Yuichiro; Anno, Takatoshi; Koyama, Katsumasa; Kawasaki, Fumiko; Kaku, Kohei; Tomoda, Koichi; Sugiyama, Seiko; Aoyama, Yumi; Kaneto, Hideaki.
Affiliation
  • Iwamoto Y; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
  • Anno T; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
  • Koyama K; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
  • Kawasaki F; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
  • Kaku K; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
  • Tomoda K; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
  • Sugiyama S; Department of Dermatology, Kawasaki Medical School, Okayama, Japan.
  • Aoyama Y; Department of Dermatology, Kawasaki Medical School, Okayama, Japan.
  • Kaneto H; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Front Immunol ; 13: 843480, 2022.
Article in En | MEDLINE | ID: mdl-35309321
Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) is relatively high in subjects with BP. It is known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind of antidiabetic drugs, can cause BP, although precise mechanism of DPP-4i-related BP remains unclear. In this report, we showed a case with appearance of various disease-specific antibodies after the onset of DPP-4i-related BP. Furthermore, various disease-specific antibodies became positive and showed high titers two years after the onset of DPP-4i-related BP and discontinuation of DPP-4i. These data showed that it is possible for immune tolerance to be broken after the onset of DPP-4i-related BP, and it may be important to check autoimmune antibodies in DPP-4i-related BP subjects even when BP symptoms are improved.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pemphigoid, Bullous / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors Type of study: Diagnostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pemphigoid, Bullous / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors Type of study: Diagnostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: Switzerland